| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Dozens of Phase III RCTs across SUSTAIN, LEADER, SCALE trial programs. Multiple network meta-analyses. FDA approved for T2D and obesity. Highest possible design quality. |
25 / 25 |
| Sample Size | LEADER trial alone enrolled 9,340 participants. SUSTAIN trials collectively tens of thousands. |
20 / 20 |
| Replication | Independently replicated by research groups across every continent. Novo Nordisk trials, academic trials, NIH-funded trials, and international registry data all converge. |
20 / 20 |
| Journal Impact Factor | Primary outcomes published in NEJM (IF ~96), JAMA (IF ~120), Lancet (IF ~98). Only compound in catalog with top-tier A-journal primary data. |
15 / 15 |
| Funding Independence | Almost entirely industry funded — Novo Nordisk funds the vast majority. Trials are pre-registered and rigorously conducted but funding picture is overwhelmingly industry. |
4 / 10 |
| Population Diversity | LEADER and SUSTAIN programs enrolled globally diverse populations across age, sex, ethnicity, and comorbidity profiles. |
5 / 5 |
| Researcher h-Index | Lead researchers include John Buse (h-Index ~120+) and Steven Nissen (Cleveland Clinic). Top tier. |
5 / 5 |